AlzeCure Selects Drug Candidate and Enters Next Phase of Development with TrkA-NAM ACD137 against Severe Pain
STOCKHOLM, SWEDEN / ACCESSWIRE / January 29, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO: ALZCUR, a pharmaceutical company that develops a broad portfolio of small molecule